Anatomic

Executive Summary

Anatomic is a San Francisco-based biotechnology company that provides researchers with access to genuine human neural tissues derived from human induced pluripotent stem cells (hiPSCs). Its core technology dramatically accelerates the production of hiPSC-derived neurons and other neural cell types, reducing manufacturing time from one month to just one week. This breakthrough addresses a critical bottleneck in neurological research and drug development, enabling faster and more predictive in vitro models for diseases such as Alzheimer's, Parkinson's, and ALS. By offering standardized, high-quality neural cells, Anatomic empowers academic and pharmaceutical customers to advance basic science and improve the success rate of CNS drug candidates. With its proprietary platform, Anatomic is poised to capture significant value in the growing digital health and diagnostics market. The company's ability to provide reproducible, physiologically relevant human neural tissues positions it as a key enabler for early-stage drug screening, toxicity testing, and disease modeling. As the demand for more human-relevant preclinical tools increases, Anatomic's technology offers a compelling alternative to animal models and traditional cell cultures. The company's focus on reducing manufacturing time and cost while maintaining high quality makes it an attractive partner for biopharma companies seeking to accelerate their neurology pipelines.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• H2 2026Pharmaceutical Partnership for Drug Screening60% success
• Q4 2026Launch of New Neural Cell Type Product75% success